Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode

Abstract Aims Renin–angiotensin–aldosterone system inhibitors (RAASi) are foundational in the management of heart failure (HF) and chronic kidney disease (CKD) but increase the risk of hyperkalaemia. To facilitate continuation of RAASi therapy, guidelines suggest managing hyperkalaemia using newer p...

Descripció completa

Dades bibliogràfiques

Autors principals:	Charles V. Pollack Jr., David Arroyo, Eiichiro Kanda, Ignacio José Sánchez Lázaro, Eva Lesén, Stefan Franzén, Christen M. Gray, Anna Lipińska, Toyoaki Murohara, Anjay Rastogi
Format:	Artigo
Idioma:	Inglês
Publicat:	Oxford University Press 2025-06-01
Col·lecció:	ESC Heart Failure
Matèries:	chronic kidney disease heart failure hyperkalaemia potassium binder renin–angiotensin–aldosterone system inhibitor sodium zirconium cyclosilicate
Accés en línia:	https://doi.org/10.1002/ehf2.15171
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!